GV 2019 GP, L.L.C. 4
4 · Verve Therapeutics, Inc. · Filed Jun 22, 2021
Insider Transaction Report
Form 4
GV 2019 GP, L.L.C.
10% Owner
Transactions
- Conversion
Series A-2 Preferred Stock
2021-06-21−37,308,792→ 0 total(indirect: By GV 2019 L.P.)→ Common Stock (4,029,244 underlying) - Conversion
Common Stock
2021-06-21+4,029,244→ 4,029,244 total(indirect: By GV 2019 L.P.) - Conversion
Common Stock
2021-06-21+443,265→ 4,472,509 total(indirect: By GV 2019 L.P.) - Conversion
Series B Preferred Stock
2021-06-21−4,104,416→ 0 total(indirect: By GV 2019 L.P.)→ Common Stock (443,265 underlying)
Footnotes (3)
- [F1]The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date.
- [F2]The reported securities are held directly by GV 2019, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote or dispose of these shares. Each of GV 2019 GP, L.P., GV 2019 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc., and Alphabet Inc. disclaim beneficial ownership of the shares except to the extent of any pecuniary interest therein.
- [F3]The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.